Le Lézard
Classified in: Health, Science and technology

Alligator Bioscience AB Reports Full Year Financial Results for 2024 and for Q4 2024 and Provides a Business Update


LUND, SE / ACCESS Newswire / January 22, 2025 / Alligator Bioscience (STO:ATORX)

Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX)

"We have continued to make notable progress with our lead asset mitazalimab over the past quarter. The positive clinical and biomarker results presented at the SITC annual meeting from the OPTIMIZE-1 trial adds to the promise of mitazalimab as a potentially groundbreaking treatment for metastatic pancreatic cancer. Our focus remains on ensuring mitazalimab reaches patients swiftly, delivering the best returns for our stakeholders, and achieving commercial success. The positive outcome from our regulatory interactions during the quarter confirms our completed and planned CMC-work as Phase 3-enabling, and marks an important step which confirms we remain on track to achieve these goals. During this quarter, we have further sharpened our focus on mitazalimab and implemented a cost-reduction program to maximize long-term value creation. We sold the future financial commitments for two bispecific antibodies to Orion Corporation, and the exercise of warrants series TO 9 brought in SEK 0.8 million. Together with the raised bridge loan and announcement of a rights issue of approximately SEK 280 million we have strengthened our financial position to ensure our continued progress. This year has seen us deliver on many important milestones, and the final quarter is no exception. We now continue our efforts to deliver outstanding results in the coming year."
Søren Bregenholt, CEO of Alligator Bioscience

BUSINESS UPDATE
Mitazalimab

ALG.APV-527

Company

FINANCIAL SUMMARY FOR Q4 2024 and FULL YEAR 2024
The financial summaries for the quarterly periods ending December 31st, 2024 and December 31st, 2023 are presented below.

All amounts in MSEK,
unless specified

October - December 2024

October - December 2023

Net sales

41.8

11.7

Operating profit/loss

-60.1

-70.4

Profit/loss for the period

-55.4

-69.8

Cash flow for the period

17.1

-7.1

Cash and cash equivalents

64.3

66.1

Earnings per share before and after dilution, SEK

-0.07

-0.11

The financial summaries for the year-to-date periods ending December 31st, 2024 and December 31st, 2023 are presented below.

All amounts in MSEK,
unless specified

January - December 2024

January - December 2023

Net sales

57.8

58.1

Operating profit/loss

-229.1

-249.0

Profit/loss for the period

-233.9

-248.6

Cash flow for the period

-1.2

-30.2

Cash and cash equivalents

64.3

66.1

Earnings per share before and after dilution, SEK

-0.32

-0.55

The full report is attached as a PDF, and is also available on the company's website: https://alligatorbioscience.se/en/investors/financial-reports/

Alligator will host a webinar on Wednesday, January 22, at 3 p.m. CEST/ 9 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the 2024 Year-end report, which will be followed by a Q&A session.

The call will be held in English. Attendees need to register by following this link .

For further information, please contact:

Søren Bregenholt, CEO
E-mail: [email protected]
Phone: +46 (0) 46 540 82 00

Johan Giléus, CFO
E-mail: [email protected]
Phone: +46 (0) 46 540 82 00

The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. CET on January 22, 2025.

About Alligator Bioscience

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com .

Attachments

2024Q4 EN 22 Jan 2025 VF

SOURCE: Alligator Bioscience



View the original press release on ACCESS Newswire


These press releases may also interest you

at 04:05
Vantage Markets is proud to announce its success at the 5th Annual Business Tabloid Awards, held on 23rd January 2025 in Dubai. The Annual Business Tabloid Awards celebrate outstanding achievements across industries, including banking, finance,...

14 fév 2025
Report on how AI is driving market transformation - The global fast fashion market size is estimated to grow by USD 79.2 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 11% during the forecast period....

14 fév 2025
Report on how AI is redefining market landscape - The global smartwatch market  size is estimated to grow by USD 46.3 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  15.5%  during the forecast period....

14 fév 2025
Report with the AI impact on market trends - The global mobile application market size is estimated to grow by USD 2.63 trillion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 31.1% during the forecast period....

14 fév 2025
Report with market evolution powered by AI - The global cryptocurrency market size is estimated to grow by USD 39.75 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  16.7%  during the forecast period....

14 fév 2025
Report on how AI is redefining market landscape - The global carbon accounting software market  size is estimated to grow by USD 33.08 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  38.5%  during the...



News published on and distributed by: